|
TEENAGERS with ADHD RESPOND to a COMBINATION
of DRUG and BEHAVIOR THERAPY
Steven W. Evans, Ph.D., William E. Pelham Jr., Ph.D., and Bradley
H. Smith, Ph.D.
Ritalin and other stimulants have become the standard treatment for
attention deficit hyperactivity disorder (ADHD) in elementary-age children
because of their ability to curb disruptive and defiant behavior and
allow children to focus. Now, a new study a finds that Ritalin also
improves daily academic performance and behavior of teenagers.
In the first empirical study of its kind, researchers Steven W. Evans,
Ph.D., and colleagues William E. Pelham Jr., Ph.D., and Bradley H. Smith,
Ph.D., found that methylphenidate (MPH)--the drug best known by the
trade name Ritalin -- in combination with a behavior modification intervention,
improved adolescent's diagnosed with ADHD performance on a range
of academic measures, including note-taking, daily assignments and quiz
scores, without causing major side effects. "When they
were taking stimulant medication, students were more likely not only
to get schoolwork done, but to get it done more accurately than when
they were taking a placebo," says Dr. Evans. "Scores improved
by an average of about 17 percent--a jump that could mean two or three
letter grades." Most research on ADHD has focused on behavioral
problems, such as disruptive or defiant behavior. But because problems
in school are one of the hallmarks of ADHD in adolescents, Evans and
his colleagues measured the effects of different doses of MPH not only
on teenagers' behavior, but also on their academic performance.
With a grant from the National Institute of Mental Health, they examined
45 adolescents diagnosed with ADHD and enrolled in a University of Pittsburgh
intensive summer treatment program, directed by Pelham, for youth with
ADHD. Because ADHD affects boys more often than girls, most of the study
participants were male. Three times per day during the eight-week
study, the researchers gave participants either a placebo or a 10-,
20- or 30-milligram dose of MPH (each day's third dose was half
the size of the first and second dose). The students received each dose
of the drug, or a placebo, for one day each week, in random order, allowing
the researchers to compare their behavior and academic performance in
each of the drug conditions. In addition to attending a one-hour
history class four days a week, all students participated in other structured
activities, such as note-taking instruction and social skills and problem
solving groups, designed to help them learn to control their behavior.
The researchers measured the quality of students' note-taking, their
performance on daily quizzes, in-class worksheets and writing assignments,
and how often they completed homework assignments. Evans' team also
observed how often students displayed disruptive, inattentive or defiant
behavior in the classroom. Results showed that MPH, when administered
as part of the intensive behavior change interventions significantly
boosted the quality of students' schoolwork. About 80 percent of
adolescents showed improved academic performance while taking some dose
of stimulant medication. The research also revealed important
individual differences in adolescents' response to the drug and
that increasing the dosage did not necessarily improve student performance.
Two-thirds of teen-agers in the study showed moderate to large improvement
in academic performance while on 10 milligrams of MPH, compared with
placebo. Of those who did not improve significantly on the lowest dose,
fewer than half showed substantial improvement when the dose was increased
to 20 milligrams, and very few students achieved significant gains on
a 30-milligram dose of the drug. In fact, some students' performance
deteriorated when their dosages of MPH increased. "That's
extremely important," stresses Pelham. "There are lots of
psychiatrists out there who believe that if you keep upping the dose,
people will continue to get better." The fact that that wasn't
the case, he explains, is important because "you want the total
amount of psychoactive drugs that a person takes in his or her lifetime
to be as low as possible, because we don't know what the long-term
effects are." "There would be a lot less controversy
about medication for ADHD if people were consistently implementing both
medication and evidence-based behavioral interventions, " suggests
Evans. He and his colleagues found the lack of research on ADHD treatment
for adolescents disturbing because, as scientists are increasingly recognizing,
the disorder continues far beyond childhood. "When children hit
puberty," Evans observes, "they go through a lot of changes--hormonally,
cognitively, emotionally and interpersonally. So there are lots of reasons
why interventions that are effective in younger children may or may
not be effective later." The authors caution that their study doesn't
indicate whether taking stimulant medications helps students' school
performance over the long term. Indeed, because it's not practical--or
indeed ethical--to conduct long-term studies in which researchers randomly
assign participants to different doses of stimulant medication or a
placebo--and because many young people stop taking medication during
adolescence--that question is particularly difficult to answer, they
note. Reference: "Dose-Response
Effects of Methylphenidate on Ecologically Valid Measures of Academic
Performance and Classroom Behavior in Adolescents with ADHD," Steven
W. Evans, Ph.D., William E. Pelham, Ph.D.,
and Elizabeth M. Gnagy, Ph.D.,
Bradley H. Smith, Ph.D., Oscar Bukstein,
Ph.D., Andrew R. Greiner, Ph.D., Lori Altenderfer, Ph.D., and Carrie
Baron-Myak, Ph.D.; Experimental
and Clinical Psychopharmacology, Vol 9, No. 2. Steven W. Evans,
PhD can be reached by telephone at (540) 568-2538.
William E. Pelham, PhD can be reached by telephone at (716) 829-2244
ext 29 or ext 31. 05/24/01
The American Psychological Association (APA), in
Washington, DC, is the largest scientific and professional organization representing
psychology in the United States and is the world's largest association of psychologists.
APA's membership includes more than 159,000 researchers, educators, clinicians,
consultants and students. Through its divisions in 50 subfields of psychology
and affiliations with 58 state, territorial and Canadian provincial associations,
APA works to advance psychology as a science, as a profession and as a means
of promoting human welfare.
|